

Listing of Claims:

1. (original): Vaccine composition containing self-TGF α or any derived or its combination with other EGF-R ligands, coupled with any carrier protein genetically or by chemical conjugation that contains an adjuvant, able to produce a specific immune response against the self-TGF α .
2. (original): Vaccine composition according to claim 1 containing recombinant human TGF α .
3. (original): Vaccine composition according to claim 1 wherein the carrier protein used is P64k.
4. (original): Vaccine composition according to claim 1 that contains a recombinant fusion protein between TGF α and P64k cloned in any expression vector system such as: mammalian cells, bacteria or yeast.
5. (original): Vaccine composition according to claim 1 that contains a recombinant fusion protein between TGF α and P64k cloned in a expression vector of bacteria and expressed in E. coli.
6. (original): Vaccine composition according to claim 1 that contains a recombinant fusion protein between hTGF α and P64k cloned in a expression vector of bacteria that presents a genetic sequence coding for six histidines in the N-terminal end of P64k and expressed in E. coli.
7. (original): Vaccine composition according to claim 1 that contains a chemical conjugated between TGF α and P64k.
8. (original): Vaccine composition according to claim 1 that contains TGF α , EGF and P64k coupled by a chemical method.
9. (original): Vaccine composition according to claim 1 that contains TGF α , EGF and P64k in a recombinant fusion protein cloned in a expression vector of bacteria and expressed in E. coli.
10. (original): Vaccine composition that represents the mix of two vaccine preparations containing the chemical conjugated between P64k and TGF α or EGF respectively in the moment of the injection

11. (original): Vaccine composition that represents the mix of two vaccine preparations containing fusion proteins between the P64k and TGF α or EGF respectively in the moment of injection.
12. (original): Vaccine composition according to claim 1 wherein the adjuvant is incomplete adjuvant of Freund.
13. (original): Vaccine composition according to claim 1 wherein the adjuvant is Al(OH)3.
14. (withdrawn): Immunization method with a vaccine composition according to claim 1, able to achieve specific antibodies against hTGF α .
15. (withdrawn): Treatment method according to claim 14, able to generate anti-hTGF α antibodies, capable of avoid the TGF α bind to its receptor in an in vitro experiment.
16. (withdrawn): Treatment method according to claim 14, able to generate anti-hEGF antibodies.
17. (withdrawn): Treatment method according to claim 14, able to generate anti-hTGF α antibodies, able of recognize TGF α in human tumor biopsies.
18. (withdrawn) Method of treatment of malignant diseases, such as epidermoide breast carcinomas, prostate, gastric, ovary epithelial cancer that express TGF α and other ligands of EGF-R, such as EGF, with a vaccine composition according to claim 1.